DMAC יחס מהיר DiaMedica Therapeutics

DiaMedica Therapeutics (DMAC) creates innovative stroke rehabilitation methods, leveraging patent protection for its developments. A tight-knit group of executives manages the company, focusing their efforts on the final stages of clinical trials. Simultaneously, the business integrates ESG principles into biopharmaceuticals while adhering to environmental standards. This chart from GURU.Markets shows that the quick ratio is 6.93, confirming the issuer's current liquidity.

Quick liquidity determines a company's ability to instantaneously settle short-term obligations using its most accessible assets. The calculation excludes slow-moving inventories, offsetting cash and accounts receivable against current liabilities. The month-over-month quick liquidity trend demonstrates financial resilience excluding inventory holdings. For DiaMedica Therapeutics (DMAC), this is a critical survival indicator, as the development of the DM199 drug depends entirely on available cash until the completion of clinical trials.